Ceranib-2 Enhanced Cisplatin Efficacy in Cancer Cells
Researchers combined Ceranib-2 with cisplatin at hyperthermic temperatures to inhibit ovarian cancer cell growth.
Updated on Oct. 6, 2026 in Cancer
A recent study found that Ceranib-2 significantly improves the cytotoxic effectiveness of cisplatin when treating OVCAR-3 ovarian cancer cells under hyperthermic conditions. This combination treatment promotes cancer cell death by inducing ER stress and autophagy.
Why it matters
The study aims to address chemoresistance in ovarian cancer treatment by using Ceranib-2 to manipulate ceramide-driven signaling pathways. This approach potentially improves the efficacy of traditional chemotherapy regimens under elevated temperatures.
The study utilized a hyperthermic temperature of 39 ˚C during the application of the combined therapy. The treatment resulted in a 4-fold upregulation of the anti-apoptotic protein Bcl-2 compared to control groups.
The players
OVCAR-3
This is a well-established human ovarian cancer cell line used in laboratory research to study drug responses and cancer progression.
The details
The treatment works by triggering programmed cell death through ceramide-driven endoplasmic reticulum stress and autophagy while reducing reactive oxygen species levels. In silico analysis suggests that Ceranib-2 specifically interacts with glutamate dehydrogenase, ultimately impairing the tumor cells' ability to form colonies and spread.
Timeline
October 6, 2026: The study was published.
The Big Picture
This research provides a new molecular basis for optimizing hyperthermic intraperitoneal chemotherapy (HIPEC) protocols. By identifying specific metabolic targets, the findings update the current understanding of how temperature-sensitive treatments can overcome cellular chemoresistance.
While these findings are currently limited to laboratory environments, they suggest a future pathway for improving the effectiveness of standard chemotherapy. If validated in clinical settings, this approach could eventually lead to more successful treatment options for patients with resistant ovarian cancer.
The takeaway
This discovery highlights how heat-based therapies can be chemically enhanced to disrupt cancer cell survival mechanisms. Researchers are moving toward more precise protocols that combine metabolic inhibitors with temperature-regulated treatments.
What happens next
Future research will focus on translating these laboratory findings into clinical trials to refine HIPEC protocols targeting ceramide metabolism.
Further reading
For additional insights into current oncology research, explore the latest Cancer reports.
More information
Access the full findings within the peer-reviewed research article.
Source note: This article includes information reported by Nature.
